Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Ronald E. Myers"'
Autor:
Hee Soon Juon, Marcella Pimpinelli, Brooke Ruane, Charnita Zeigler-Johnson, Russell K. McIntire, Christine S. Shusted, Julie A. Barta, Gregory C. Kane, Nathaniel R. Evans, Ronald E. Myers
Publikováno v:
Clinical Lung Cancer. 22:570-578
One challenge in high-quality lung cancer screening (LCS) is maintaining adherence with annual and short-interval follow-up screens among high-risk individuals who have undergone baseline low-dose CT (LDCT). This study aimed to characterize attitudes
Autor:
Emily Lambert, Sarah E. Hegarty, Rebecca Jackson, Anna Quinn, Melissa DiCarlo, Anett Petrich, Randa Sifri, Rhea E. Powell, Ronald E. Myers, Katherine Sherif, Sandra Dayaratna
Publikováno v:
Menopause. 28:1060-1066
OBJECTIVE To develop a decision support intervention that can be used with women experiencing menopausal symptoms to facilitate treatment shared decision making. METHODS Our research team contacted patients with reported menopausal symptoms by teleph
Autor:
Melissa DiCarlo, Pamela Myers, Constantine Daskalakis, Ayako Shimada, Sarah Hegarty, Charnita Zeigler-Johnson, Hee-Soon Juon, Julie Barta, Ronald E. Myers
Publikováno v:
Preventive medicine. 159
Current guidelines recommend annual lung cancer screening (LCS), but rates are low. The current study evaluated strategies to increase LCS. This study was a randomized controlled trial designed to evaluate the effects of patient outreach and shared d
Autor:
Andrea M. Barsevick, Scott W. Keith, Ronald E. Myers, Evan Lapinsky, Amy R. MacKenzie, Sarah E. Hegarty, Sheel Patel, Andrew E. Chapman, Joshua Schoppe, Ulysses Williams Iii
Publikováno v:
J Geriatr Oncol
Autor:
Baskaran Sundaram, Christine S. Shusted, Ronald E. Myers, Gregory C. Kane, Michael Lake, Teresa E. Giamboy, Nathaniel R. Evans, Brooke Ruane, Rickie Brawer, Julie A. Barta
Publikováno v:
Population Health Management
Patient navigation has been proposed to combat cancer disparities in vulnerable populations. Vulnerable populations often have poorer cancer outcomes and lower levels of screening, adherence, and treatment. Navigation has been studied in various canc
Autor:
Anett Petrich, Nicole A Fournakis, Claudine Jurkovitz, Nora Katurakes, Heather Bittner Fagan, Ronald E. Myers, Zugui Zhang
Publikováno v:
Journal of Cancer Education
The national rate of lung cancer screening, approximately 3–5%, is too low and strategies which include shared decision-making and increase screening are needed. A feasibility study in one large primary care practice of telephone-based delivery of
Autor:
Ronald E. Myers, Neha Pancholy, Xiaobing Chen, Zhenchao Zhang, Lifang Hou, Hushan Yang, Theodore N. Tsangaris, Chun Wang, Frederick M. Fellin, Zhaomei Mu, Jinliang Xing, Juan P. Palazzo, Manish Neupane, Daniel P. Silver, Qiang Wei, Rebecca Jaslow, Massimo Cristofanilli, Xiuhong Fu, Max Krall, Inna Chervoneva, Adam C. Berger, Saveri Bhattacharya, Shaogui Wan, Laura Austin, Darayus Toorkey, Maysa M. Abu-Khalaf, Zhong Ye, Xiuling Li, Bingshan Li, Kaelan Yao
Publikováno v:
European Journal of Cancer. 106:133-143
BACKGROUND: Both circulating tumor cell (CTC) and total circulating cell-free DNA (ccfDNA) predict cancer patient prognosis. However, no study has explored the prognostic value of the combined use of CTC and ccfDNA. We aimed to investigate individual
Autor:
Ronald E. Myers
Publikováno v:
Chest
BACKGROUND: The Centers for Medicare and Medicaid Services stipulate shared decision-making (SDM) counseling as a prerequisite to lung cancer screening (LCS) reimbursement, despite well-known challenges implementing SDM in practice. RESEARCH QUESTION
Autor:
Robert Pilarski, Arthur L. Burnett, Lucia R. Languino, Colette Hyatt, Jacqueline Powers, Robert B. Den, Alberto Briganti, Veda N. Giri, Lorelei A. Mucci, Daniel P. Petrylak, Oliver Sartor, Amie Blanco, Daniel W. Lin, Himisha Beltran, E. David Crawford, Karen E. Knudsen, Mary-Ellen Taplin, Brian T. Helfand, Felix Y. Feng, Costas D. Lallas, E. Michael D. Scott, Wayne H. Pinover, R. Jeffrey Karnes, Scott Weissman, Evan Y. Yu, Timothy R. Rebbeck, Ashley H. Woodson, Matthew J. Schiewer, Todd M. Morgan, William B. Isaacs, Jeffrey N. Weitzel, Alanna Kulchak Rahm, Michael S. Cookson, James A. Eastham, S. Bruce Malkowicz, Neha Vapiwala, Kevin R. Loughlin, Raoul S. Concepcion, Ana Maria Lopez, Jose Moreno, Brock O'Neil, Patrick T. Gomella, Patrick Mille, Charnita Zeigler-Johnson, Howard M. Sandler, Kathleen A. Cooney, William Tester, Sarah M. Nielsen, Thomas J. Polascik, Richard C. Wender, Howard R. Soule, Ronald E. Myers, Scott E. Eggener, Marc B. Garnick, Stacy Loeb, Martin Miner, Anthony J. Costello, Gerald L. Andriole, Amanda E. Toland, David Y.T. Chen, Albert Dobi, Joseph K Izes, Mary B. Daly, Leonard G. Gomella, Mark D. Hurwitz, J. Kellogg Parsons, Matthew L. Freedman, Nathan Handley, Adam P. Dicker, Jianfeng Xu, Michael Russell Mullane, Charles J. Ryan, Edouard J. Trabulsi, Anne Calvaresi, James Ryan Mark, Thenappan Chandrasekar, Colin C. Pritchard, Saud H. AlDubayan, Curtis A. Pettaway, William Kevin Kelly, Lindsey Byrne, Peter R. Carroll, Brittany M. Szymaniak, Alicia K. Morgans, Peter A. Pinto, William L. Dahut, Mark Mann, Ganesh V. Raj, James L. Mohler, Wendy Poage, Heather H. Cheng, Grace L. Lu-Yao
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 24
PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a0090e4e87cd120ef0899e6263c77c
https://escholarship.org/uc/item/3mg229rb
https://escholarship.org/uc/item/3mg229rb
Autor:
Daniel P. Silver, Weelic Chong, Geetha Jagannathan, Frederick M. Fellin, Kaelan Yao, Terrence P. Cescon, Maysa M. Abu-Khalaf, Chun Wang, Zhaomei Mu, Brian Lu, Manish Neupane, Ana Maria Lopez, Adam C. Berger, Rebecca Jaslow, Massimo Cristofanilli, Saveri Bhattacharya, Ronald E. Myers, Zhenchao Zhang, Qiang Wei, Bingshan Li, Zhong Ye, Theodore N. Tsangaris, Hushan Yang, Lifang Hou, Juan P. Palazzo
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2(−)/cHER2(+) can benefit from anti-HER2 targeted